Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 169  

    Article Cited by others

ORIGINAL ARTICLE

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years

Assadi Majid, Rezaei Samira, Jafari Esmail, Rekabpour Seyed Javad, Ravanbod Mohammad Reza, Zohrabi Farshad, Amini AbdulLatif, Keshmiri Saeid, Dadgar Habibollah, Ahmadzadehfar Hojjat

Year : 2020| Volume: 19| Issue : 1 | Page no: 15-20

   This article has been cited by
 
1 Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study
Milka Marinova,Reza Alamdar,Hojjat Ahmadzadehfar,Markus Essler,Ulrike Attenberger,Martin Mücke,Rupert Conrad
Nuklearmedizin. 2020;
[Pubmed]  [Google Scholar] [DOI]
2 Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis
Finn Edler von Eyben,Glenn Bauman,Rie von Eyben,Kambiz Rahbar,Cigdem Soydal,Alexander R. Haug,Irene Virgolini,Harshad Kulkarni,Richard Baum,Giovanni Paganelli
International Journal of Molecular Sciences. 2020; 21(23): 9054
[Pubmed]  [Google Scholar] [DOI]

 

Read this article